Literature DB >> 8086734

Growth and skeletal maturation in children with phenylketonuria.

F Schaefer1, P Burgard, U Batzler, A Rupp, H Schmidt, G Gilli, H Bickel, H J Bremer.   

Abstract

Growth and skeletal maturation was evaluated in 82 children participating in the German Collaborative Study of Children Treated for Phenylketonuria (PKU). Height, weight, head circumference and bone age were recorded at regular intervals for the first 6 years of life. The mean SD score (SDS) for height was not significantly different from zero at study entry, but decreased mainly during the second year of life to a nadir of -0.78 in boys and -0.54 in girls at 2.5 years. During the subsequent years, a significant trend towards a regain of height SDS was noted in both sexes. Weight-for-height SDS was close to zero in both sexes, with a significant continuous increasing trend throughout the observation period. Head circumference SDS decreased in boys during the first year of life from -0.28 to -0.68, whereas girls showed only a minor change. During the further follow-up period, head circumference SDS remained at approximately -0.3 in boys and 0.0 in girls. While the mean verbal and performance IQ of the total study population at 5 and 6 years of age did not differ from a group of 212 healthy non-PKU children, patients with a head circumference SDS less than the population median at 2 years of age exhibited poorer cognitive abilities at school age than those patients with a relative head size greater than the population median. The children with a head circumference less than the median at 2 years had smaller head sizes already at birth; in addition, the change in relative head size during the first 2 years was correlated significantly with cognitive abilities at school age in boys. Mean bone age was identical to chronological age at each time point of observation. The rate of maturation was one year of bone age per year of chronological age. No correlation between phenylalanine intake or phenylalanine concentrations and the rates of body or head growth or skeletal maturation could be established. We conclude that despite adequate weight gain, moderate growth retardation occurred during the first 2 years of life in this group of children treated for PKU. Growth was more compromised in boys than in girls and tended to be compensated during later follow-up. Early infantile head circumference and growth appear to be predictors of cognitive development.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8086734     DOI: 10.1111/j.1651-2227.1994.tb13075.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  16 in total

1.  Bone development in children and adolescents with PKU.

Authors:  A B Mendes; F F Martins; W M S Cruz; L E da Silva; C B M Abadesso; G T Boaventura
Journal:  J Inherit Metab Dis       Date:  2011-11-11       Impact factor: 4.982

2.  The intake of total protein, natural protein and protein substitute and growth of height and head circumference in Dutch infants with phenylketonuria.

Authors:  M Hoeksma; M Van Rijn; P H Verkerk; A M Bosch; M F Mulder; J B C de Klerk; T J de Koning; E Rubio-Gozalbo; M de Vries; P J J Sauer; F J van Spronsen
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

3.  Elevated plasma phenylalanine concentrations may adversely affect bone status of phenylketonuric mice.

Authors:  S Yannicelli; D M Medeiros
Journal:  J Inherit Metab Dis       Date:  2002-09       Impact factor: 4.982

4.  Comparison of the protein quality of dietetically treated phenylketonuria patients with the recommendations of the WHO Expert Consultation.

Authors:  G Krauch; E Müller; A Anninos; H J Bremer
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

5.  Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria.

Authors:  P Burgard; E Schmidt; A Rupp; W Schneider; H J Bremer
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

6.  Recommendations for protein and energy intakes by patients with phenylketonuria.

Authors:  P B Acosta
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

7.  Evaluation of nutritional status and pathophysiology of growth retardation in patients with phenylketonuria.

Authors:  D Dobbelaere; L Michaud; A Debrabander; S Vanderbecken; F Gottrand; D Turck; J P Farriaux
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 8.  Growth and body composition in children with classical phenylketonuria: results in 34 patients and review of the literature.

Authors:  M Huemer; C Huemer; D Möslinger; D Huter; S Stöckler-Ipsiroglu
Journal:  J Inherit Metab Dis       Date:  2007-07-11       Impact factor: 4.982

Review 9.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

Review 10.  Mild hyperphenylalaninemia: to treat or not to treat.

Authors:  Francjan J van Spronsen
Journal:  J Inherit Metab Dis       Date:  2011-02-24       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.